MX2017014162A - Una composicion farmaceutica antiviral de uso topico. - Google Patents

Una composicion farmaceutica antiviral de uso topico.

Info

Publication number
MX2017014162A
MX2017014162A MX2017014162A MX2017014162A MX2017014162A MX 2017014162 A MX2017014162 A MX 2017014162A MX 2017014162 A MX2017014162 A MX 2017014162A MX 2017014162 A MX2017014162 A MX 2017014162A MX 2017014162 A MX2017014162 A MX 2017014162A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
topical use
antiviral pharmaceutical
antiviral
quaternary ammonium
Prior art date
Application number
MX2017014162A
Other languages
English (en)
Inventor
Alberto Argañaras Luis
Original Assignee
Quim Luar S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quim Luar S R L filed Critical Quim Luar S R L
Publication of MX2017014162A publication Critical patent/MX2017014162A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Abstract

Una composición farmacéutica antiviral de uso tópico contra aquellos virus con envoltura lipídica, que comprende como principios activos un copolímero catiónico conteniendo grupos aminos terciarios, y un tensioactivo catiónico conteniendo grupos amonios cuaternarios.
MX2017014162A 2015-05-15 2016-05-13 Una composicion farmaceutica antiviral de uso topico. MX2017014162A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP150101519A AR100459A1 (es) 2015-05-15 2015-05-15 Una composición farmacéutica antiviral de uso tópico
PCT/ES2016/070365 WO2016185069A1 (es) 2015-05-15 2016-05-13 Una composición farmacéutica antiviral de uso tópico

Publications (1)

Publication Number Publication Date
MX2017014162A true MX2017014162A (es) 2018-06-20

Family

ID=57319498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014162A MX2017014162A (es) 2015-05-15 2016-05-13 Una composicion farmaceutica antiviral de uso topico.

Country Status (11)

Country Link
US (1) US10478452B2 (es)
EP (1) EP3295934B1 (es)
AR (1) AR100459A1 (es)
BR (1) BR112017024399B1 (es)
CL (1) CL2017002796A1 (es)
CO (1) CO2017011297A2 (es)
ES (1) ES2915824T3 (es)
IL (1) IL255635A (es)
MX (1) MX2017014162A (es)
PE (1) PE20180396A1 (es)
WO (1) WO2016185069A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022219944A1 (ja) * 2021-04-16 2022-10-20 株式会社日本触媒 抗コロナウイルス剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743727A (en) * 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4902720A (en) * 1983-01-10 1990-02-20 Baldone Joseph A Treatment of virus infections with quaternary ammonium compounds
US5160737A (en) * 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
BRPI0014271B1 (pt) * 1999-09-24 2021-06-22 Janssen Pharmaceutica N.V. Partícula consistindo em uma dispersão de sólidos, uso da dita partícula, dispersão de sólidos, forma de dosagem farmacêutica, bem como processos de preparação de dita partícula, dispersão e forma de dosagem
US6855341B2 (en) 2002-11-04 2005-02-15 Jeffrey B. Smith Anti-viral compositions and methods of making and using the anti-viral compositions
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
ITMI20051417A1 (it) * 2005-07-22 2007-01-23 Mipharm S P A Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
US8119115B2 (en) * 2006-02-09 2012-02-21 Gojo Industries, Inc. Antiviral method
US7883487B2 (en) * 2008-06-16 2011-02-08 Shantha Totada R Transdermal local anesthetic patch with injection port
US20140328895A1 (en) * 2011-03-29 2014-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Film-forming composition for a ph-dependant sustained release of the active agent

Also Published As

Publication number Publication date
WO2016185069A1 (es) 2016-11-24
US20180250327A1 (en) 2018-09-06
CO2017011297A2 (es) 2018-01-31
BR112017024399A2 (pt) 2019-02-05
IL255635A (en) 2018-01-31
EP3295934A1 (en) 2018-03-21
EP3295934B1 (en) 2022-03-02
ES2915824T3 (es) 2022-06-27
EP3295934A4 (en) 2019-01-02
BR112017024399B1 (pt) 2022-06-07
CL2017002796A1 (es) 2018-07-13
AR100459A1 (es) 2016-10-05
PE20180396A1 (es) 2018-02-28
US10478452B2 (en) 2019-11-19

Similar Documents

Publication Publication Date Title
EP3315608A4 (en) Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
WO2017100063A3 (en) Stable ready-to-drink beverage compositions comprising lipophilic active agents
MY196308A (en) PTH Prodrugs
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
WO2015173427A3 (fr) Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
CO2017007316A2 (es) Formulación farmacéutica
MX2020012989A (es) Agente terapeutico para la fibrosis.
EP3630174A4 (en) COMPOSITIONS INCLUDING MODIFIED HIV ENVELOPES
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
MX2017014162A (es) Una composicion farmaceutica antiviral de uso topico.
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
EP3257881A4 (en) Fluorinated copolymer, and surface modifier containing same as active ingredient
WO2016113752A3 (en) Liquid formulation of cabazitaxel
MX2014015199A (es) Formulacion de pexiganan estable.
BR112017018707A2 (pt) composições compreendendo compostos de mentol como agentes suavizantes
CO2017003989A2 (es) Composición herbicida y proceso para prepararla
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
MY202277A (en) Intranasal composition of methylcobalamin
IL246606B (en) Mir-122 as an active micro-rna, compounds containing it and its uses.
TR201618030T2 (tr) Tadı düzeltilmiş parasetamol formülasyonları.
PH12017501982A1 (en) Pharmaceutical compound
PL399592A1 (pl) Kompozycja farmaceutyczna do stosowania miejscowego zawierajaca acyklowir oraz sposób jej wytwarzania
Lee Activities through Eco-friendiy Packaging